Literature DB >> 10654529

Low-molecular-weight heparin for prosthetic heart valves: treatment failure.

O Lev-Ran1, A Kramer, J Gurevitch, I Shapira, R Mohr.   

Abstract

There is no adequate substitute therapy for patients with prosthetic heart valves, in whom anticoagulation with warfarin or unfractionated heparin must be withheld. In the literature there are several reports describing successful treatment with low-molecular-weight heparin in patients with prosthetic heart valves. We report two cases of low-molecular-weight heparin treatment failure resulting in thrombosed prosthetic heart valves with stormy clinical presentations, who underwent successful valve replacements.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10654529     DOI: 10.1016/s0003-4975(99)00874-7

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

Review 1.  Marfan's syndrome.

Authors:  Daniel P Judge; Harry C Dietz
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

2.  Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.

Authors:  Amir K Jaffer; Mudassar Ahmed; Daniel J Brotman; Lee Bragg; Niranjan Seshadri; Mohammed A Qadeer; Allan Klein
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

Review 3.  Anticoagulation for mechanical heart valves in patients with and without atrial fibrillation.

Authors:  Usman Baber; Sarina van der Zee; Valentin Fuster
Journal:  Curr Cardiol Rep       Date:  2010-03       Impact factor: 2.931

4.  Valvular Heart Disease in the Pregnant Patient.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-02

Review 5.  Antithrombotic therapy for prosthetic valves: routine treatment and special considerations.

Authors:  A M Al-Ahmad; D Hartnett-Daudelin; D N Salem
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

6.  Current options for treatment of chronic coronary artery disease.

Authors:  Sotirios N Prapas; Kosmas Tsakiridis; Paul Zarogoulidis; Nikolaos Katsikogiannis; Theodora Tsiouda; Antonios Sakkas; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.